PRMT5 and breast cancer: The effects of GSK3326595 in lymphoma and breast cancer cell lines suggest that PRMT5 inhibition results in context-dependent effects on cell cycle (a 2 N population increase was observed only in a subset of sensitive models, while a decrease in 2 N and an increase in 4 N was observed in MDA-MB-468).